#### Check for updates

#### OPEN ACCESS

EDITED BY Rudolf Lucas, Augusta University, United States

REVIEWED BY Michael Wilson, Imperial College London, United Kingdom Jona Walk, Radboud University Medical Centre, Netherlands

\*CORRESPONDENCE Johnny Amer ∑j.amer@najah.edu

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 17 September 2024 ACCEPTED 09 December 2024 PUBLISHED 07 January 2025

#### CITATION

Amer J, Salhab A and Abuawad M (2025) Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin  $D_3$ : a promising therapeutic approach. *Front. Immunol.* 15:1466802. doi: 10.3389/fimmu.2024.1466802

#### COPYRIGHT

© 2025 Amer, Salhab and Abuawad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin D<sub>3</sub>: a promising therapeutic approach

Johnny Amer<sup>1\*†</sup>, Ahmad Salhab<sup>2†</sup> and Mohammad Abuawad<sup>2</sup>

<sup>1</sup>Department of Allied Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine, <sup>2</sup>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine

**Background and aim:** NK cells and NK-cell-derived cytokines were shown to regulate neutrophil activation in acute lung injury (ALI). However, the extent to which ALI regulates lung tissue-resident NK (trNK) activity and their molecular phenotypic alterations are not well defined. We aimed to assess the impact of 1,25-hydroxy-vitamin-D3 [1,125(OH)<sub>2</sub>D] on ALI clinical outcome in a mouse model and effects on lung trNK cell activations.

**Methods:** Oleic acid (OA)-induced ALI in C57BL/6J mice and 1,25(OH)<sub>2</sub>D treatment 2×/2 weeks were performed. Lung tissue was harvested to assess alveolar I/II cell apoptosis and lung injury marker of Surfactant-Protein-D (SP-D). Pulmonary edema markers of epithelial sodium channel, cystic fibrosis transmembrane conductance regulator, and aquaporin 5 were assessed by RT-PCR. Lung trNK cells were assessed for activation markers of CD107a and NKp46, vitamin D receptor (VDR), and programmed cell death protein-1 (PD-1) via flow cytometry. The bronchoalveolar lavage fluid (BALF) obtained was investigated for soluble receptor for advanced glycation end products (sRAGE), inflammatory cytokines, soluble 1,25(OH)<sub>2</sub>D, and PDL-1. Naïve mice treated with DMSO (vehicle) were used as a control.

**Results:** Flow cytometry analysis displayed a high apoptotic rate in alveolar I/II cells of threefold in ALI mice as compared to naïve mice. These findings were accompanied by elevated markers of pulmonary edema as well as lung injury markers of SP-D. Isolated lung trNK cells of the ALI mice exhibited reduced CD107a and NKp46 markers and cytotoxicity potentials and were correlated through significantly 2.1-fold higher levels of PD-1 and diminished VDR expressions as compared to naïve mice. BALF samples of ALI mice displayed high soluble PDL-1 and reduced soluble 1,25(OH)<sub>2</sub>D levels compared to naïve mice. 1,25(OH)<sub>2</sub>D treatment alongside OA led to a significant fourfold increase in the CD107a and NKp46 expressions to levels higher than the mice treated with the vehicle. Furthermore, 1,25(OH)<sub>2</sub>D ameliorates free radical scavengers of GSH, GPX, CAT, and GPx-1; decreased pro-inflammatory cytokines and soluble PDL-1; and increased soluble 1,25(OH)<sub>2</sub>D with amelioration in pulmonary edema markers and alveolar I/II apoptosis.

**Conclusion:** Our results indicate  $1,25(OH)_2D$ 's potential therapeutic effect in preventing clinical outcomes associated with ALI via regulating NK cells through inhibiting inflammatory cytokines and alleviating levels of PDL-1 and  $1,25(OH)_2D$  released by lung tissue.

KEYWORDS

lung injury, 1, 25(OH)2D, NK cells, VDR, PD-1, PDL-1

## Introduction

Acute lung injury (ALI) is a condition characterized by sudden and severe respiratory compromise, often progressing to acute respiratory distress syndrome (ARDS) (1). It represents a critical form of pulmonary dysfunction with significant morbidity and mortality rates (2). The pathophysiology of ALI involves a complex interplay of inflammatory mediators, oxidative stress, and endothelial dysfunction (3). Alveolar epithelial cell damage and the infiltration and activation of inflammatory cells such as neutrophils and macrophages contribute to releasing proinflammatory cytokines and chemokines (4). This inflammatory cascade leads to increased vascular permeability, pulmonary edema, and impaired surfactant function, culminating in severe hypoxemia and respiratory failure (5).

 $1,25(OH)_2D$ , the active form of vitamin D<sub>3</sub>, plays a crucial role beyond its classical functions in calcium homeostasis and bone metabolism (6). It exerts pleiotropic effects on various tissues and cells throughout the body, including those in the respiratory system (7). In recent years, research has revealed its potential therapeutic implications in conditions such as ALI and ARDS (8). One of the key mechanisms by which 1,25(OH)<sub>2</sub>D exerts its effects is through binding to the vitamin D receptor (VDR), which is expressed in a wide range of cells, including epithelial cells, immune cells, and endothelial cells within the lung (9). Upon binding to VDR, 1,25(OH) <sub>2</sub>D modulates gene expression, leading to immunomodulatory, antiinflammatory, and cytoprotective effects (10-13). While 1,25(OH)<sub>2</sub>D has garnered attention as a potential therapeutic agent in ALI (11-17), its specific effects on natural killer (NK) cells and the molecular pathways regulating these effects remain largely unknown. NK cells are innate immune cells that play a crucial role in host defense against pathogens and in immune surveillance against tumor cells (18). Emerging evidence suggests that 1,25(OH)<sub>2</sub>D may modulate NK cell function, potentially impacting the immune response in ALI (19). It is hypothesized that 1,25(OH)<sub>2</sub>D may exert its effects through various molecular pathways involved in immune regulation, including the modulation of cytokine production, cell signaling pathways, and gene expression profiles within NK cells. In this study, we aimed to assess the molecular effects of 1,25(OH)<sub>2</sub>D on ALI mouse models and their impacts on resident lung NK cells' activity in an approach to attenuate inflammation and improve clinical outcomes in ALI.

## Methods

#### Animal ethics and study design

The animals used in our experimental procedures were housed in a barrier facility and received care according to the An-Najah National University ethical regulations and NIH guidelines. The institutional animal care ethics committee of the An-Najah National University approved all animal protocols under the ethics number 2024-02-01. Mice groups: Group 1: Naive mice with no treatment of either OA and 1,  $25(OH)_2D$  treatment and received only intraperitoneal (i.p.) injection of DMSO (0.01%) as vehicle, twice weekly for 2 weeks. Group 2: Naive mice treated with  $1,25(OH)_2D$  (100 ng/kg), i.p. injection twice a week for 2 weeks. Group 3: ALI mice treated with OA (150 µL/kg), intravenous (i.v.) injection twice a week for 2 weeks. Group 4: ALI mice treated parallelly with both OA (150 µL/kg) and 1,  $25(OH)_2D$  (100 ng/kg). Each mouse group had n = 11.

#### Acute lung injury animal model

The acute lung injury model was introduced in 12-week-old male wild-type C57BL/6J mice (weighing 25 ± 1.5 g) by i.v. injection of oleic acid (OA; Merck, O1008-1G >99% purity, as determined by LC/ MS analyses) at a concentration of 150  $\mu$ L/kg twice a week for 2 weeks using special microsyringes to ensure precise and accurate delivery of the small injection volume (3.5  $\mu$ L/25 g mouse weight). DMSO and 1,25(OH)<sub>2</sub>D treatment was prepared fresh daily in phosphate-buffered saline (PBS) at a concentration volume of 100  $\mu$ L.

#### Animal experimental setting

Mice and diet were weighed, and water intake was measured daily. Prior to sacrifice, animals were anesthetized by 5% isoflurane inhalation for 10 s before cervical dislocation. On the day of sacrifice, lung bronchoalveolar lavage fluid (BALF) extracts were assessed for sRAGE, soluble PDL-1, soluble 1,25(OH)<sub>2</sub>D, and proinflammatory cytokine profile assessments by enzyme-linked immunosorbent assay (ELISA). As described below, mRNA was obtained from the lung for gene expression assessment. Lung tissueresident NK (trNK) cells were assessed using flow cytometry.

# Bronchoalveolar lavage fluid extraction from lung tissues

The trachea was surgically exposed and intubated with a syringe catheter. The lungs went through lavage with 1 mL of pre-warmed PBS five times. A total of 5 mL of BALF was obtained from each mouse, and cells in BALF were pelleted by centrifugation (500 g for 10 min at 4°C). Cells were then resuspended in cold PBS, counted, and immediately applied to subsequent analyses. The supernatants were stored at -80°C for BAs measurements.

### Cytokine assessment in BALF

A multiplexed sandwich enzyme-linked immunosorbent assaybased technology (Cat# MHSTCMAG-70K; R&D Systems) was used to simultaneously determine the concentration of multiple cytokines of IL-1β, TNF-α, IL-6, and IL-4 in BALF. In addition, sRAGE concentrations were assessed using an ELISA kit (Cat# Abcam; ab197745), and soluble PDL-1 and 1,25(OH)2D concentrations were assessed using Cat# Abcam; ab210971 and Cat# Abcam; ab213966, respectively. All reagents and samples were brought to room temperature (18-25°C) before use. A volume of 100 µL of each standard and BALF sample was added into appropriate wells and incubated for 2.5 h at room temperature with gentle shaking. The solution was discarded, and wells were washed four times with 1× wash solution. Notably, washing was done by filling each well with wash buffer (300 µL) using a multi-channel Pipette or auto washer. After washing, the liquid was completely removed at each step, which is essential for good performance. A volume of 100 µL of 1× prepared detection antibody was added to each well for 1 hour at room temperature with gentle shaking. A volume of 100 µL of prepared streptavidin solution was added to each well for 45 min at room temperature with gentle shaking. A volume of 100 µL of TMB One-Step Substrate Reagent (Item H) was added to each well for 30 min at room temperature in the dark with gentle shaking. Finally, 50 µL of stop solution (Item I) was added to each well. Absorbance was read at 450 nm immediately using an ELISA reader (Tecan M100 Plate Reader). In addition, cells were counted using light microscopy in multiple fields, and the average number of cells per field was calculated.

## Lung tissue-resident NK cell isolations

Under deep ether anesthesia, mice were euthanized by isoflurane, USP 100% (INH), and then the lung was removed, and a part of it was transferred to a Petri dish that contains 5 mL of DMEM medium (Biological Industries; Cat# 01-055-1A). The tissues were thoroughly dissected by stainless steel mesh, the cells were harvested with the medium and added to 50-mL tubes containing 10 mL of DMEM, and then carefully cells were transferred to new tubes that contained Ficoll (Abcam; Cat# AB18115269). Tubes were centrifuged for 20 min at 1,600 rpm at 20°C. The buffy coat (interphase layer) in each tube was transferred to a new tube for another 10 min, at 1,600 rpm at 4°C. After the second centrifuge, the pellet in each tube was suspended in 1 mL of DMEM for the NK isolation kit (Stem Cells; Cat# 19665). Lung trNK cells were phenotyped as CD45<sup>+</sup>CD3<sup>-</sup>NK1.1<sup>+</sup>CD49a<sup>+</sup>CD69<sup>+</sup>CD103<sup>+</sup> by flow cytometry, as mentioned below.

The viability of the lung trNK cells ( $10^6/100 \mu$ L) was assessed by propidium iodide (PI) (A35110, R&D Systems) staining. PI-negative cells were considered viable when the mean viability rate of the cells was above 90%.

## Flow cytometry

All used antibodies were incubated with the isolated cell suspensions (1:100) at 4°C for 45 min; cells were washed with 2× PBS with 1% FCS before the secondary antibody (1:100) at 4°C for 45 min if required. Primary mouse antibodies used are anti-CD45 (ab10558, abcam), anti-CD3 (ab33429, abcam), anti-NK1.1 (ab289542, abcam), anti-CD49a (142605, BioLegend), anti-CD69 (104505, BioLegend), anti-CD103 (121405, BioLegend), anti-CD107a [lysosomal-associated membrane protein-1 (LAMP-1) (ab24170, abcam)], anti-NKp46 (ab83946, abcam), anti-PD-1 (ab214421, abcam), and anti-VDR (ab3508, abcam). Isotype IgG labeled with the relevant fluorochrome was used as a control for each antibody. Prior to flow cytometry analysis, cells with a count of  $10^{6}/100 \ \mu L$  were assessed for their viability measured by PI (A35110, R&D Systems). PI-negative cells were considered viable, and the mean viability rate of the cells was 92.7%  $\pm$ 1.5%. All stained cells were examined on a flow cytometer (BD LSR Fortessa<sup>TM</sup>, Becton Dickinson, Immunofluorimetry Systems) and analyzed by FCS Express 7 by De Novo Software for Flow Cytometry.

### TrNK cytotoxicity assay

K562 cells, a human leukemia cell line, were used as target cells in a cytotoxicity assay to evaluate the activity of lung trNK cells. The assay was performed by coculturing NK cells with K562 cells at a 4:1 effector-to-target ratio for 6 h as described by Lisovsky et al. (20) After the coculture incubation, the cells were stained with NK cell markers, including NK1.1, and Annexin V to assess apoptosis. The alveolar cells were identified as negative for NK1.1 expression, confirming their non-NK cell phenotype. Apoptosis was evaluated by detecting Annexin V binding.

## RNA isolation, cDNA preparation, and realtime PCR

A total cellular count of 10  $\mu g/\mu L$  RNA (purity 98%) determined using a Nanodrop ND-1000 spectrophotometer

(Nanodrop Technologies, Wilmington, DE) was isolated from all mouse groups (n = 11) using 2 mL of TRI reagent (Bio Lab; Cat# 90102331). The samples were centrifuged (1,400 rpm) for 15 min at 4°C to collect RNA supernatant. For RNA precipitation, the supernatant of each sample was transferred to a new microcentrifuge tube, and 0.5 mL of isopropanol (Bio Lab; Cat# 16260521) was added and incubated at 25°C for 10 min. The tubes were then centrifuged (12,000 rpm) for 10 min at 4°C, the supernatants were removed, and 1 mL of 75% ethanol was added to the pellets prior to centrifugation (7,500 rpm) for 5 min. The pellets were air-dried at room temperature for 15 min, 50 µL of DEPC was added, and the samples were heated for 10 min at 55°C. cDNA was prepared with a High-Capacity cDNA Isolation Kit (R&D; Cat# 1406197). Real-time PCR was performed with TaqMan Fast Advanced Master Mix (Cat# 4371130, Applied Biosystems) to quantify SP-D, ENaC, CFTR, and AQP-5 gene expressions with normalization to the expression of the housekeeping gene GAPDH. Cycling conditions for the Thermofisher one-step RT-PCR kit involved RT steps for 30 min at 50°C and denaturation for 15 min at 95°C. Furthermore, the reaction mixture was incubated for 40 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min, followed by 72°C for 10 min. Data analysis was carried out using the QuantStudio<sup>TM</sup> 5 Real-Time PCR System (Cat# A34322, Applied Biosystems).

#### Lung oxidant and antioxidant activity assay

The homogenized lung tissue was centrifuged at 9,000 g for 15 min. The separated supernatant was used for oxidative stress assessment of malondialdehyde (MDA) and free radicals' scavengers of glutathione (GSH), glutathione peroxidase (GPX), catalase (CAT), and glutathione peroxidase activity (GP×1) were determined using an ELISA kit according to the manufacturer's instructions.

### Alveolar epithelial cell isolation and phenotyping

Both type I (AT-I) and type II (AT-II) alveolar epithelial cells were isolated from mice lungs, as described by Chen et al. (21), and sorted using FACSAria III Cell Sorter (BD FACSAria), as defined by Gonzalez et al. (22) Mice were euthanized, and the lungs were harvested and inflated with a collagenase-based digestion buffer to separate the alveolar epithelial cells. The lung tissue was minced and incubated in the digestion buffer at 37°C with constant agitation to dissociate the cells. After digestion, the tissue was filtered through a 70-µm mesh to remove debris. The resulting single-cell suspension was subjected to differential centrifugation to enrich epithelial cells. AT-I cells were distinguished by positivity for anti-mouse aquaporin 5 (Abcam; Cat# 315855) while AT-II cells were identified using anti-mouse epithelial cell adhesion molecule (EpCAM, Abcam; Cat# ab221552) and anti-mouse surfactant protein C antibody (SP-C, Abcam; Cat# 211326). The staining was confirmed by comparable staining patterns following the use of isotype IgG labeled with the relevant fluorochrome (isotype negative control). AT-1 and AT-II viability was assessed by PI staining according to the kit instructions (A35110, R&D Systems). Samples  $\geq$ 90% PI-negative cells were considered viable. Apoptosis was evaluated with annexin V (A35110, R&D Systems) staining. Early apoptotic cells were defined as annexin V<sup>+</sup>PI<sup>-</sup> cells, and late apoptotic cells were defined as annexin V<sup>+</sup>PI<sup>-</sup> cells. All stained cells were examined by flow cytometry with a BD LSR Fortessa Cell Analyzer (Becton Dickinson, Immunofluorometry Systems) and analyzed using FCS Express 7 with *De Novo* Software for flow cytometry.

### Statistical analysis

Statistical differences were analyzed with a two-tailed unpaired Student's *t*-test (for comparisons between two groups) or two-way analysis of variance (ANOVA) with GraphPad Prism 9.0 (GraphPad Software, La Jolla, CA). A *t*-test of *p*-value  $\leq 0.05$  is considered statistically significant and was calculated as the difference in means between two variables. Results are presented as mean  $\pm$  SD or as average means of experimental replicates  $\pm$  SD.

## Results

# 1,25(OH)<sub>2</sub>D alleviates lung injury markers outcome in a mouse model of ALI

1,25(OH)<sub>2</sub>D effects on OA-induced ALI mice were assessed for their potential therapeutic effects via determining ALI markers of inflammatory, fibrotic, oxidative, and apoptotic markers. Surfactant Protein D (SP-D), a marker for interstitial lung diseases (ILDs) and ARDS (23), exhibited a significant increase of 2.5-fold in mice administered with 0.15 mL/kg OA. These elevations showed a decrease of 1.47-fold following treatment with 100 ng/kg 1,25 (OH)<sub>2</sub>D (Figure 1A). No effects of 1,25(OH)<sub>2</sub>D were seen in the naive mice. Moreover, alveolar cell apoptosis, an important mechanism in ALI progressions, was assessed in isolated alveolar I (AT-1) and alveolar II (AT-II) cells. Supplementary Figure S1 displays representative flow cytometry dot blot analysis of the lung cell isolate that was used in identifying AT-I and AT-II cells using gating strategies and specific antibodies as indicated in Materials and Methods. Flow cytometry analysis displayed a high apoptotic rate in both AT-1 and AT-II cells threefold as presented in Figures 1B, C, respectively (p < 0.0001). These findings were restored in the mice treated with 1,25(OH)<sub>2</sub>D to levels comparable to naïve mice treated with vehicle. Impaired and extensive epithelial injury results in the inflammatory phase of ALI (24). Therefore, to further characterize whether 1,25(OH)<sub>2</sub>D modulates the inflammatory outcome, sRAGE, involved in the inflammatory response during ALI effects, as well as proinflammatory cytokines, were assessed in BALF samples obtained from our mouse groups. Figures 1D, E display a significant increase in sRAGE, IL-1 $\beta$ , TNF- $\alpha$ , IL-6, and IL-4 in the OA-treated mice of 4- to 10-fold (p < 0.001). Nonetheless, 1,25(OH)<sub>2</sub>D treatments were shown to attenuate BALF sRAGE levels through a 1.46-fold



reduction as compared to naïve mice. Moreover,  $1,25(OH)_2D$  decreased pro-inflammatory cytokines, suggesting the antiinflammatory effects of  $1,25(OH)_2D$  in defending against insults of OA and reducing inflammatory markers associated with ALI.

Pulmonary edema results from a combination of both increased fluid filtration and impairment of transepithelial Na+ transport (25). Therefore, we sought to assess whether  $1,25(OH)_2D$  could inhibit OA-augmented edema formation. Epithelial sodium channel (ENaC), cystic fibrosis transmembrane conductance regulator (CFTR), and aquaporin 5 (AQP5) were assessed. Figure 1F illustrates an increase in ENaC, CFTR, and AQP5 levels in the OA-treated mice of 2.3-, 1.7-, and 1.67-fold, respectively (p <0.01). In contrast,  $1,25(OH)_2D$  treatments reduced ENaC expressions by twofold, while CFTR and AQP5 showed an inhibition following the  $1,25(OH)_2D$  treatment to levels comparable to the naïve mice.

The effects of OA on mice and lung weight were assessed daily within the experiment's duration. OA caused a reduction in weight relative to mice treated with vehicles. Conversely, mice receiving both OA and 1,25(OH)<sub>2</sub>D demonstrate a restored weight to levels comparable to naïve mice receiving the vehicle (Supplementary Figure S2A). Concerning lung weight, mice treated with OA significantly increased lung weight. On the other hand, 1,25(OH)<sub>2</sub>D treatment exhibits a substantial reduction in lung weight,

comparable to naïve mice receiving the vehicle (Supplementary Figure S2B).

# Biomarker of oxidative stress and antioxidant defense

Recent reports regarding the canonical role of oxidative stress in the development of ALI (26). The imbalance between the production of free radicals and their elimination by antioxidants was described as the major protective mechanism against OAinduced-ALI (27). To test the antioxidant effects of 1,25(OH)<sub>2</sub>D, we initially examined MDA activity in serum and lung tissue samples following OA treatment. Table 1 demonstrates an increase in serum as well as lung tissue MDA of 2.8- and 3.8-fold, respectively, as compared to naïve mice (p < 0.05). However, administration of 1,25 (OH)<sub>2</sub>D along OA caused a significant reduction of MDA levels in serum and lung tissue of 1.8- and 5.3-fold, respectively (p < 0.05). To further define the association of the antioxidant effects of 1,25 (OH)<sub>2</sub>D in preventing OA-induced ALI, the levels of free radical scavengers GSH, SOD, CAT, and GSH-Px were assessed in both serum and lung tissue samples. Table 1 illustrates that these antioxidant markers were significantly lower in serum and lung tissue samples from OA-treated mice than in naïve mice (p < 0.05).

Group		MDA	GSH	SOD	CAT	GSH-Px
		(mmol/L)	(mmol/mL)	(U/L)	(U/L)	(U/L)
		(nmol/g tissue)	(nmol/g tissue)	(U/g)	(U/g)	(U/g)
Naive	Serum	$4.28 \pm 0.27$	$157.23 \pm 10$	241 ± 55	$60.45 \pm 3.5$	$50.32 \pm 3.5$
	Lung	$3.18 \pm 0.22$	141. $\pm 4$	200 ± 18	$82.8 \pm 6$	$40.23 \pm 6$
Naive + 1,25(OH) <sub>2</sub> D	Serum	5.22 ± 0.29*	166 ± 9.3	$233.7 \pm 25$	68.5 ± 3.6*	54.35 ± 1.5*
	Lung	4.52 ± 0.26	132 ± 11.6	$210 \pm 0.3$	79.6 ± 7*	49.6 ± 3.3
OA	Serum	$12.19 \pm 0.35^{*}$	92.3 ± 45*	$154.5 \pm 16^{*}$	$22 \pm 0.18^{*}$	$12.2 \pm 6^{*}$
	Lung	$12.3 \pm 0.15^{*}$	81.3 ± 9*	60 ± 9 <sup>*</sup>	$33.3 \pm 0.25^{*}$	21.5 ± 6.3*
OA + 1,25(OH) <sub>2</sub> D	Serum	$6.76 \pm 0.6^{\#}$	$133.3 \pm 9^{\#}$	$181.35 \pm 8^{\#}$	$71.3 \pm 5.1^{\#}$	$60.3 \pm 1.3^{\#}$
	Lung	$2.31 \pm 0.9^{\#}$	$127.35 \pm 13^{\#}$	$167 \pm 12^{\#}$	$67 \pm 2.3^{\#}$	$36.25 \pm 3.2^{\#}$

TABLE 1 A multiplexed sandwich enzyme-linked immunosorbent assay-based technology was used to determine the concentration of MDA, GSH, SOD, CAT, and GSH-PX in serum and lung tissue.

Data are represented as averages  $\pm$  SD (n = 11 per group). Significance was determined using *t*-test analysis, \**p*-value <0.05 between the naïve group and OA group, #*p*-value <0.05 between the OA group and OA treated with 1,25(OH)<sub>2</sub>D group.

However, when mice of ALI were treated with 1,25(OH)<sub>2</sub>D, a significant increase in the levels of 1.4- to 2.0-fold of these antioxidant markers was noticed compared to ALI mice with OA alone (p < 0.05). Overall, our findings suggest that 1,25(OH)<sub>2</sub>D boosts the antioxidant defense system against OA-induced ALI and emphasizes the role of free radicals in ALI pathogenesis.

# Molecular pathways of 1,25(OH)<sub>2</sub>D improving lung NK cell cytotoxicity in ALI

Diffuse alveolar damage (DAD) is the dominant pathological feature of ALI (28). Moreover, one of the pathological features of ALI includes uncontrolled inflammatory response during immune and neutrophil movement (29), a process that is in part shown to be controlled by NK cells through producing pulmonary CXCL1 and CXCL2 (30); however, NK cell's function and factors influencing its activity in ALI are still underestimated. We attempted to assess lung NK cells' cytotoxic role in ALI progressions following OA treatment. Supplementary Figure S3 displays illustration on flow cytometry phenotype analysis of lung trNK cell isolates and tested markers for NKp46 and CD107a. Figure 2A displays the distribution of lung trNK cells represented as counts and percentages assessed by flow cytometry. Lung trNK cells showed a severe reduction in their percentages by 6.0-fold following OA treatment as compared to the naïve mice. In contrast, following 1,25 (OH)<sub>2</sub>D treatment, lung trNK cells showed a comparable and elevated distribution percentage as seen in the naïve mice treated vehicle.

To further investigate trNK cells' activity in correlation to their elevated count distribution in lung tissue following  $1,25(OH)_2D$ , trNK cell activation markers of CD107a and NKp46 were assessed. Our findings reveal a marked decrease in the expression levels of CD107a and NKp46 markers in mice treated with OA of 2.5-folds (Figure 2B) and 2.1-folds (Figure 2C), respectively, compared to those treated with DMSO alone. Furthermore,  $1,25(OH)_2D$ treatment alongside OA led to a significant 4-fold increase in the CD107a and NKp46 expressions to levels higher than the mice treated with the vehicle. Furthermore, we associate trNK activity with their potential cytotoxicity effects through a coculture assay of these cells with K562 cells, and the K562 cell's apoptotic rate was investigated. Figure 2D demonstrates that K562 cells cocultured with lung NK cells of ALI had an apoptosis percentage of  $10\% \pm$ 2.2%, similar to K562 monoculture represented in the dotted horizontal line. Lung trNK cells of ALI treated with 1,25(OH)<sub>2</sub>D increased the K562 apoptosis rate to 38.4% ± 5.4%. Conversely, K562 cocultured with lung trNK cells from the naïve mice treated with 1,25(OH)<sub>2</sub>D remained with the same apoptotic rate as compared to naïve mice receiving the vehicle (p = ns). Our findings suggest 1,25(OH)2D's effect on promoting trNK cell activation and its cytotoxic potentials, consequently inducing K562 killing. However, these results do not fully explain the factors affecting NK cell impairment in ALI.

To assess phenotypic alterations that occurred in lung NK cells of ALI, we assessed PD-1 expressions and VDR on NK cells. PD-1positive NK cells have been shown to exhibit a weaker antitumor function than that of PD-1-negative NK cells in lung cancer (31). However, their role in regulating NK activity in ALI is still not addressed. Moreover, the VDR is shown to be expressed in most immune cells (32), while its expression on lung NK cells is not documented, and how vitamin D enhances immune effector pathways of NK cells is still unknown.

Figure 3A demonstrates that lung trNK cells of the ALI mouse model exhibited significantly 2.1-fold higher levels of PD-1 than naïve mice. Moreover, 1,25(OH)2D treatment displayed a significant decrease in lung trNK cell PD-1 expression levels to levels similar to naïve mice treated or untreated with 1,25(OH)<sub>2</sub>D. On the other hand, lung NK cells expressed diminished VRD in the ALI mouse model and had expressions of  $8\% \pm 1.9\%$  compared to 18%  $\pm$  4.1% in naïve mice (Figure 3B, p < 0.05). Lung trNK cells isolated from the ALI treated with 1,25(OH)<sub>2</sub>D exhibited VDR expressions of  $26\% \pm 7.2\%$ . Naïve mice with and without 1,25(OH)<sub>2</sub>D treatment had similar VDR on lung trNK cells. These results, in part, could indicate (1) 1,25(OH)<sub>2</sub>D as an immune effector in enhancing trNK cell activity, (2) alteration in lung phenotypic alteration in the ALI mouse model, and (3) inverse association of trNK cell activity with PD-1 and positive association between lung VRD and trNK activity. Nevertheless, our current data are still



Flow cytometry analysis of (A) lung trNK cells and activation markers of (B) CD107a and (C) NKp46 assessed in all mouse groups. (D) Cytotoxic assay of lung trNK cells through cell incubation with K562 as a target cell in the ratio of (4:1) for 6 h, then K562 cell apoptosis was assessed through annexin-V<sup>+</sup>/Pl<sup>-</sup> detection by flow cytometry analysis. Data are represented as averages  $\pm$  SD (n = 11 per group). Significance was determined using Newman–Keuls two-way analysis of variance (ANOVA), \*p < 0.01, \*\*p < 0.001, \*\*\*p < 0.0001, \*\*\*\*p < 0.00001.

inadequate for explaining regulatory factors influencing lung trNK cell activity in ALI. Soluble factors present in the lung that can regulate trNK cell activity include TGF- $\beta$  (33), prostaglandins produced by alveolar macrophages (34), and pulmonary surfactant (35).

Considering the alteration in lung NK cell expressions of PD-1 and VDR in ALI, we sought to determine levels of soluble PDL-1 in BALF samples as the major ligand of PD-1 that are shown in many studies to be dominantly expressed on alveolar cells and alveolar macrophages (36). Moreover, we suggested assessing for soluble 1,25(OH)<sub>2</sub>D, as suggested by Zheng et al., and its role in attenuating lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis, and inhibiting induced epithelial-to-mesenchymal transition (37). Figure 3C indicates highly detected levels of soluble PDL-1 79.5%  $\pm$  7.6% pg/mL in the ALI compared to 9.7%  $\pm$  2.5% pg/mL in the naïve mice (p < 0.05). In contrast, reduced levels of soluble  $1,25(OH)_2D$  in BALF samples of ALI were noticed with a concentration of  $1.4\% \pm 0.4\%$  pg/mL as compared to  $12.3\% \pm$ 3.0% (Figure 3D). The ALI mouse model treated with  $1,25(OH)_2D$ caused a reduction in soluble PDL-1 of 2.1-fold and an elevation in soluble  $1,25(OH)_2D$  of 10.3-fold to comparable levels seen in the naïve mice. Overall results indicate  $1,25(OH)_2D$ 's potential therapeutic effects in preventing clinical outcomes associated with ALI via regulating NK cells through inhibiting inflammatory cytokines and alleviating levels of PDL-1 and vitamin D released by lung tissue.

## Discussion

Inflammation in ALI can be triggered through both exogenous pathways, including toll-like receptors (TLRs), and endogenous



pathways related to members of the damage-associated molecular pattern (DAMP) released by dead cells or local inflammatory cells (29). However, the involvement and association of  $1,25(OH)_2D$ , the active form of vitamin D<sub>3</sub>, in the regulatory role of NK cells in a mouse model of ALI was not well established prior to our current study. We investigated the role of  $1,25(OH)_2D$  in modulating the activity of lung trNK cells within the context of ALI induced by OA. ALI and its severe manifestation, ARDS, present intricate challenges in clinical management, necessitating a deeper understanding of the underlying pathophysiology and potential therapeutic interventions (38). Our study sheds light on the immunomodulatory effects of  $1,25(OH)_2D$  on NK cells and its implications for ALI management.

NK cells are pivotal components of the innate immune system, tasked with surveilling and eliminating virally infected cells and tumor cells (39). Upon infection, rapid NK cell infiltration into the lungs occurs, the amplitude of which is determined by the extent of inflammation and damage (40). Activated NK cells kill infected cells

and produce pro-inflammatory cytokines and chemokines to recruit cells of the adaptive immune system (41). However, their dysregulation or impairment can exacerbate tissue injury and inflammation in various pathological conditions, including ALI (42). Our findings unveil the immunomodulatory effects of  $1,25(OH)_2D$  in alleviating trNK cell function via CD107a and NKp46 and phenotypic alteration through the assessment of crucial receptors, such as PD-1 and VDR on trNK cells that are important in defining the regulatory destination of lung trNK cells and consequently influencing the pathogenesis of ALI.

Recent evidence shows that immune cells and cytokines secreted by immune cells play an irreplaceable role in the pathogenesis of acute lung injury (29). Cytokines such as TNF- $\alpha$ and interleukins (mainly IL-1 $\beta$  and IL-6) are important mediators in the development of ARDS, contributing to augmented vascular permeability and organ dysfunction (43). Our data evidently showed the effects of 1,25(OH)<sub>2</sub>D in ameliorating the overall rate of alveolar fluid transport reflected by the tested expression of ENaC, NKA, and CFTR. Reactive oxygen and nitrogen species (RONS) can modify or damage ion channels, such as epithelial sodium channels, which alter fluid balance, a phenomenon that was suggested by our study to be reversed through the boosting of antioxidant markers of GSH, SOD, CAT, and GSH-Px following 1,25(OH)<sub>2</sub>D treatment. Mokrá et al. showed that the flow of protein edema fluid into the alveoli can lead to the inactivation of surfactants and the loss of the protective layer on the alveolar surface, thus destroying the surface cell structure (44).

Overall, our study unveils the multifactorial clinical outcome of ALI on regulating NK activity in particularly soluble mediators in BALF samples, while 1,25(OH)<sub>2</sub>D alleviates this outcome and attenuates NK cytotoxicity, suggesting its role in the resolution of inflammation mediated in part by NK cells.

Further translational and clinical studies are warranted to offer promising insights into  $1,25(OH)_2D$ -based therapies for ALI management.

# Conclusion

Our study findings indicate an association between  $1,25(OH)_2D$  treatment and reduced clinical outcomes associated with alveolar cell apoptosis, inflammation, and pulmonary edema in ALI. This improvement correlated with an increase in VDR and a decrease in PD-1 expression on trNK cells, potentially influencing NK cell activity. These results underscore the immunomodulatory effects of  $1,25(OH)_2D$ , linked to its anti-inflammatory and antioxidative properties. While these findings are promising, further research is necessary to determine whether these associations directly contribute to improved outcomes and to fully understand the therapeutic potential of  $1,25(OH)_2D$  in ALI.

## Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

## **Ethics statement**

The animal study was approved by the institutional animal care ethics committee of the An-Najah National University under the ethics number 2024-02-01. The study was conducted in accordance with the local legislation and institutional requirements.

## Author contributions

JA: Conceptualization, Investigation, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing. AS: Data curation, Formal analysis, Methodology, Validation, Writing – review & editing. MA: Formal analysis, Investigation, Visualization, Writing – review & editing.

# Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

# Conflict of interest

The authors state that the research was conducted without any commercial or financial relationships that could be perceived as a potential conflict of interest. This declaration suggests that the study was.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024. 1466802/full#supplementary-material

#### SUPPLEMENTARY FIGURE 1

Flow cytometry dot blot analysis of (A) mice lung cells isolate gated as "gate 1" including viable cells as illustrated by SSC-A and FSC-A. (B) Dot plots of cells obtained from gate 1 representing AT-1 as indicated as positive staining for anti-mouse aquaporin 5 (AQP5) and gated as "gate 2". (C) Dot blot analysis illustrating double positive cells obtained from gate 2 for Annexin-V (ANNV) and Propidium Iodide (PI) as indicators for early apoptosis (ANNV+PI-) and late apoptosis (ANNV+PI+) as indicate in materials and methods. Flow cytometry dot blot analysis of (D) mice lung cells isolate gated as "gate 1" including viable cells as illustrated by SSC-A and FSC-A. (E) Dot plots of cells obtained from gate 1 representing AT-II as a double positive staining for anti-mouse epithelial adhesion molecule (EpCAM) and anti-mouse surfactant protein C antibody (SP-C) and gated as "gate 2". (F) Dot blot analysis illustrating double positive cells obtained from gate 2 for Annexin-V (ANNV) and Propidium Iodide (PI) as indicator for early apoptosis (ANNV+PI-) and late apoptosis (ANNV+PI-) and late apoptosis (ANNV+PI-) and a indicator for early apoptosis (ANNV+PI-) and late apoptosis (ANNV+PI+) as indicate in materials and methods.

#### SUPPLEMENTARY FIGURE 2

(A) At the termination of the experiment, mice were sacrificed, and their weight was measured in grams. (B) Following the experimental timeline, lungs from each mouse were carefully harvested, and their weights in grams were measured. Data are represented as averages  $\pm$  SD (n = 11 per group). Significance was determined using Newman–Keuls two-way analysis of variance (ANOVA), \*\*p < 0.001, \*\*\*p < 0.0001, \*\*\*p < 0.0001.

#### SUPPLEMENTARY FIGURE 3

Representative flow cytometry dot blot analysis of **(A)** NK cells following isolation by NK isolation Kit following Buffy coat isolates following Ficoll-Paque, cells were gated as "gate 1". **(B)** Cells obtained from gate 1 were stained for NK1.1-FITC (NK maker) and CD3-APC (pan T-cell marker) for assessing NK purification and a "gate 2" was set on these cells. These cells were also positive for CD45 (data not shown). TrNK cells from gate 2 were identified for CD103+CD69+ cells, a gate was set on these cells as "gate 3". **(C-E)** NK cells from gate 3 were identified for NKp46 and CD107a.

# References

1. Shi J, Tang J, Liu L, Zhang C, Chen W, Qi M, et al. Integrative analyses of bulk and single-cell RNA seq identified the shared genes in acute respiratory distress syndrome and rheumatoid arthritis. *Mol Biotechnol.* (2024). doi: 10.1007/s12033-024-01141-6

 Mowery NT, Terzian WTH, Nelson AC. Acute lung injury. Curr Probl Surg. (2020) 57:100777. doi: 10.1016/j.cpsurg.2020.100777

3. Bezerra FS, Lanzetti M, Nesi RT, Bezerra Nagato AC, Silva CPE, Kennedy-Feitosa, et al. Oxidative stress and inflammation in acute and chronic lung injuries. *Antioxidants (Basel).* (2023) 12:548. doi: 10.3390/antiox12030548

4. Tao H, Xu Y, Zhang S. The role of macrophages and alveolar epithelial cells in the development of ARDS. *Inflammation*. (2023) 46:47–55. doi: 10.1007/s10753-022-01726-w

5. Hussain M, Khurram Syed S, Fatima M, Shaukat S, Saadullah M, Alqahtani A, et al. Acute respiratory distress syndrome and COVID-19: A literature review. *J Inflammation Res.* (2021) 14:7225–42. doi: 10.2147/JIR.S334043

6. Anoušek J, Pilařová V, Macáková K, Nomura A, Veiga-Matos J, Silva DDD, et al. Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. *Crit Rev Clin Lab Sci.* (2022) 59:517–54. doi: 10.1080/10408363.2022.2070595

7. Grzelak T, Mikołajczyk K. Pleiotropic effect of vitamin D in cystic fibrosis. AdvRespir Med. (2018). doi: 10.5603/ARM.a2018.0029

8. Ragel EJ, Harris LK, Campbell RA. Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses-a systematic review. *BMJ Open Respir Res.* (2023) 10: e001525. doi: 10.1136/bmjresp-2022-001525

9. Mathyssen C, Aelbrecht C, Serré J, Everaerts S, Maes K, Gayan-Ramirez G, et al. Local expression profiles of vitamin D-related genes in airways of COPD patients. *Respir Res.* (2020) 21:137. doi: 10.1186/s12931-020-01405-0

10. Holick MF, Mazzei L, García Menéndez S, Martín Giménez VM, Al Anouti F, Manucha W. Genomic or non-genomic? A question about the pleiotropic roles of vitamin D in inflammatory-based diseases. *Nutrients.* (2023) 15:767. doi: 10.3390/ nu15030767

11. Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R. Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020\_166. *J Steroid Biochem Mol Biol.* (2020) 202:105719. doi: 10.1016/j.jsbmb.2020.105719

12. Elamir YM, Amir H, Lim S, Rana YP, Lopez CG, Feliciano NV, et al. A randomized pilot study using 1,25(OH)2D in hospitalized COVID-19 patients. *Bone.* (2022) 154:116175. doi: 10.1016/j.bone.2021.116175

13. Mansouri A, Kowsar R, Zakariazadeh M, Hakimi H, Miyamoto A. The impact of 1,25(OH)2D and estradiol on the SARS-CoV-2 biological activity: a molecular modeling approach. *Sci Rep.* (2022) 12:717. doi: 10.1038/s41598-022-04778-y

14. Zheng Y, Hu R, Hu J, Feng L, Li S. Protective effects of butorphanol in oleic acidendotoxin "two-hit" induced rat lung injury by suppression of inflammation and apoptosis. *Sci Rep.* (2024) 14:14231. doi: 10.1038/s41598-024-53483-5

15. Yan X, Li Y, Choi YH, Wang C, Piao Y, Ye J, et al. Protective effect and mechanism of alprostadil in acute respiratory distress syndrome induced by oleic acid in rats. *Med Sci Monit.* (2018) 24:7186–98. doi: 10.12659/MSM.909678

16. Kumar S, Bhagat P, Pandey S, Pandey R. The role of antioxidant agent (N-acetylcysteine) in oleic acid-induced acute lung injury in a rat model. *Cureus*. (2022) 14: e29478. doi: 10.7759/cureus.29478

17. Mishra P, Pandey R, Pandey N, Tripathi S, Tripathi YB. Prevention of mortality in acute lung injury induced by oleic acid: Application of polyherbal decoction (bronco T). *Front Cell Dev Biol.* (2022) 10:1003767. doi: 10.3389/fcell.2022.1003767

18. Yu Y. The function of NK cells in tumor metastasis and NK cell-based immunotherapy. *Cancers (Basel).* (2023) 15:2323. doi: 10.3390/cancers15082323

19. Salhab A, Amer J, Yinying L, Safadi R. 25(OH) D3 alleviate liver NK cytotoxicity in acute but not in chronic fibrosis model of BALB/c mice due to modulations in vitamin D receptor. *BMC Gastroenterol.* (2020) 20:102. doi: 10.1186/s12876-020-01248-5

20. Lisovsky I, Isitman G, Bruneau J, Bernard NF. Functional analysis of NK cell subsets activated by 721.221 and K562 HLA-null cells. *J leukocyte Biol.* (2015) 97:761–7. doi: 10.1189/jlb.4AB1014-499R

21. Chen Q, Liu Y. Isolation and culture of mouse alveolar type II cells to study type II to type I cell differentiation. *STAR Protoc.* (2020) 2:100241. doi: 10.1016/j.xpro.2020.100241

22. Gonzalez RF, Dobbs LG. Isolation and culture of alveolar epithelial Type I and Type II cells from rat lungs. *Methods Mol Biol.* (2013) 945:145–59.

23. Xu J, Wang J, Wang X, Tan R, Qi X, Liu Z, et al. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. *Cell Death Dis.* (2020) 11:934. doi: 10.1038/s41419-020-03139-9

24. Manicone AM. Role of the pulmonary epithelium and inflammatory signals in acute lung injury. *Expert Rev Clin Immunol.* (2009) 5:63-75. doi: 10.1586/1744666X.5.1.63

25. Weidenfeld S, Kuebler WM. Cytokine-regulation of na+-K+-cl- cotransporter 1 and cystic fibrosis transmembrane conductance regulator-potential role in pulmonary inflammation and edema formation. *Front Immunol.* (2017) 8:393. doi: 10.3389/fimmu.2017.00393

26. Rojo de la Vega M, Dodson M, Gross C, Mansour HM, Lantz RC, Chapman E, et al. Role of nrf2 and autophagy in acute lung injury. *Curr Pharmacol Rep.* (2016) 2:91–101. doi: 10.1007/s40495-016-0053-2

27. Chen S, Zheng S, Liu Z, Tang C, Zhao B, Du J, et al. Endogeous sulfur dioxide protects against oleic acid-induced acute lung injury in association with inhibition of oxidative stress in rats. *Lab Invest.* (2015) 95:142–56. doi: 10.1038/labinvest.2014.147

28. Kao KC, Hu HC, Chang CH, Hung CY, Chiu LC, Li SH, et al. Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy. *Crit Care*. (2015) 19:228. doi: 10.1186/s13054-015-0949-y

29. Zhu W, Zhang Y, Wang Y. Immunotherapy strategies and prospects for acute lung injury: Focus on immune cells and cytokines. *Front Pharmacol.* (2022) 13:1103309. doi: 10.3389/fphar.2022.1103309

30. Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL. 17 $\beta$ -estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs. *J Virol.* (2014) 88:4711–20. doi: 10.1128/JVI.02081-13

31. Niu C, Li M, Zhu S, Chen Y, Zhou L, Xu D, et al. PD-1-positive Natural Killer Cells have a weaker antitumor function than that of PD-1-negative Natural Killer Cells in Lung Cancer. *Int J Med Sci.* (2020) 17:1964–73. doi: 10.7150/ijms.47701

32. Arora J, Wang J, Weaver V, Zhang Y, Cantorna MT. Novel insight into the role of the vitamin D receptor in the development and function of the immune system. *J Steroid Biochem Mol Biol.* (2022) 219:106084. doi: 10.1016/j.jsbmb.2022.106084

33. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. *Nat Immunol.* (2005) 6:600–7. doi: 10.1038/ni1197

34. Lauzon W, Lemaire I. Alveolar macrophage inhibition of lung-associated NK activity: involvement of prostaglandins and transforming growth factor-beta 1. *Exp Lung Res.* (1994) 20:331–49.

35. Wilsher ML, Hughes DA, Haslam PL. Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity. *Clin Exp Immunol.* (1988) 74:465–70.

36. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. (2016) 375:1767–78. doi: 10.1056/NEJMra1514296

37. Zheng S, Yang J, Hu X, Li M, Wang Q, Dancer RCA, et al. Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF- $\beta$  induced epithelial to mesenchymal transition. *Biochem Pharmacol.* (2020) 177:113955. doi: 10.1016/j.bcp.2020.113955

38. Sinha P, Bos LD. Pathophysiology of the acute respiratory distress syndrome: insights from clinical studies. *Crit Care Clin.* (2021) 37:795-815. doi: 10.1016/j.ccc.2021.05.005

39. Burrack KS, Hart GT, Hamilton SE. Contributions of natural killer cells to the immune response against Plasmodium. *Malar J.* (2019) 18:321. doi: 10.1186/s12936-019-2953-1

40. Franklin M, Connolly E, Hussell T. Recruited and tissue-resident natural killer cells in the lung during infection and cancer. *Front Immunol.* (2022) 13:887503. doi: 10.3389/fimmu.2022.887503

41. Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. *Front Immunol.* (2017) 8:1124. doi: 10.3389/fimmu.2017.01124

42. Mian MF, Lauzon NM, Stämpfli MR, Mossman KL, Ashkar AA. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. *J Leukoc Biol.* (2008) 83:774–84. doi: 10.1189/jlb.0707481

43. Faraj SS, Jalal PJ. IL1 $\beta$ , IL-6, and TNF- $\alpha$  cytokines cooperate to modulate a complicated medical condition among COVID-19 patients: case-control study. *Ann Med Surg (Lond).* (2023) 85:2291–7. doi: 10.1097/MS9.0000000000000679

44. Mokrá D. Acute lung injury - from pathophysiology to treatment. *Physiol Res.* (2020) 69:S353–66. doi: 10.33549/physiolres.934602